Oklahoma City, OK Clinical Trials Report — June 2026

For Oklahoma City residents considering participation in clinical research, June 2026 presents a mix of urgent opportunities and significant new avenues for contributing to medical science. Across Oklahoma City, a number of trials are nearing their enrollment deadlines, making prompt action essential for interested individuals.

A total of 28 clinical trials are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 2 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various neurological and oncological conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Major depressive disorder (2 trials)
• Stroke (2 trials)
• Advanced malignant neoplasm (1 trial)
• Advanced solid tumor (1 trial)
• Aggression (1 trial)
• Agitation, psychomotor (1 trial)
• AML (1 trial)
• Alzheimer disease (1 trial)
• AML with mutated NPM1 (1 trial)
• Asthma (1 trial)

New Research Opportunities Emerge

This month, Oklahoma City saw the opening of 10 new clinical trials, a significant increase from the 2 trials that launched in May 2026. This brings the total number of actively recruiting clinical trials in Oklahoma City, OK, to 594 across 231 research facilities, underscoring the city's growing research landscape.

June brings several high-profile new trials to Oklahoma City, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Kallyope Inc. is initiating a notable Phase 3 study, NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This double-blind, randomized, multicenter trial aims for 1,800 participants to evaluate the efficacy, safety, and tolerability of elismetrep compared with placebo in the acute treatment of migraine.
• Also from Kallyope Inc., NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," is a Phase 3 study seeking 1,000 participants to evaluate the long-term safety and tolerability of intermittent use of elismetrep for acute migraine attacks.
• AstraZeneca is sponsoring NCT07652658, "A Phase IIb Study to Evaluate AZD8965 in Participants With IPF." This Phase 2b study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with Idiopathic Pulmonary Fibrosis (IPF), including those on antifibrotic therapy, and is recruiting 359 participants.
• The Office of the Medical Director for EMS in Oklahoma City and Tulsa is sponsoring NCT07632430, "End-Tidal CO2 (ETCO2) Trends in Out-of-Hospital Cardiac Arrest." This study aims to assess the relationship between patient characteristics, prehospital treatments, and vital signs to determine if EtCO2 values or trends predict patient survival to discharge, involving 3,500 participants.
• The University of Alabama at Birmingham is sponsoring NCT07671937, "INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study." This study seeks to characterize multidisciplinary tumor board context, evaluate the relationship between cancer patients' baseline fitness and initial treatment recommendations, and assess the impact of the INSPIRE intervention, with 2,748 participants.

New trials this month are exploring a range of conditions, with one trial each for acute migraine, AI-assisted colonoscopy, amyloid pathology, breast cancer, cardiac arrest (out-of-hospital), chronic wounds, corpus uteri cancer, diabetic foot, diabetic foot ulcers (DFUs), and end-tidal carbon dioxide. Drug trials account for the largest share of new studies, with 4 new drug trials, followed by 3 device trials and 1 behavioral study. 3 trials are categorized as 'OTHER'.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. A total of 1 of the 10 new trials launched this month is actively seeking healthy volunteers. Across Oklahoma City, a total of 35 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research. Remember, 2 healthy volunteer trials are closing soon, so prompt inquiry is recommended for those opportunities.

Oklahoma City's Leading Research Facilities

Oklahoma City is home to some of the state's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Oklahoma Health Sciences Center (190 trials)
• Mercy Hospital Oklahoma City (59 trials)
• University of Oklahoma (28 trials)
• Research Site (20 trials)
• OU Health Stephenson Cancer Center (17 trials)
• Stephenson Cancer Center (16 trials)
• Oklahoma Medical Research Foundation (13 trials)
• The University of Oklahoma Health Sciences Center (12 trials)
• Hightower Clinical (10 trials)
• Oklahoma Heart Hospital (9 trials)
• Integris Southwest Medical Center (6 trials)
• TSET Health Promotion Research Center (5 trials)

These institutions offer a broad spectrum of research, from comprehensive medical studies at the University of Oklahoma Health Sciences Center to specialized care at OU Health Stephenson Cancer Center and Oklahoma Heart Hospital.

Broadening Your Search: Nearby Options

While Oklahoma City offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Oklahoma. Cities with active trials include Tulsa (8 trials), Yukon (4 trials), Edmond (2 trials), and Moore (2 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 10 new trials launched this month, all 10 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial includes children. No new trials are exclusively for females or males. Academic institutions continue to play a vital role in Oklahoma City's research ecosystem, with the University of Oklahoma sponsoring 4 new trials. Industry sponsors like Kallyope Inc. (2 trials) and AstraZeneca (1 trial) are also driving significant research efforts.

As we move through June, Oklahoma City's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.